Evidence map›Paper›PMID 41211004›Full record

ArticlemHealth2025

MyGauch

Majdolen Istaiti, Elena Shulman, Tama Dinur, Dafna Frydman, Linda Harnevo, Moshe Farin, Ari Zimran, Shoshana Revel-Vilk

Abstract read
In one paragraph

Article in mHealth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Majdolen IstaitiGaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
Elena ShulmanGaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
Tama DinurGaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
Dafna FrydmanGaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
Linda HarnevoLifeOnKey Ltd., Tel-Aviv, Israel.
Moshe FarinLifeOnKey Ltd., Tel-Aviv, Israel.
Ari ZimranGaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
Shoshana Revel-VilkGaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.ORCID https://orcid.org/0000-0001-9151-0337

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gaucher disease (GD) is a rare genetic disorder caused by variants in the Methods: With input from GD experts and patient groups, the INTEGRA Results: The study enrolled 90 adults with GD1 who received ERT or SRT and had access to the necessary technology. The improvement in satisfaction with the medical management of the GD with the use of MyGauch Conclusions: Although the development of MyGauch

Indexed as

enzyme replacement therapy (ERT)Gaucher disease (GD)mobile apppatient-reported outcome measuressubstrate reduction therapy (SRT)

Identifiers

PMID41211004
PMCPMC12594012

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.